At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 248 enrolled
Drug / intervention
Fluticasone furoate 50mcg +1 moredrug
Likely dose
Fluticasone furoate 50mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Not Currently Receiving Inhaled Corticosteroids
In Brief
A Phase 3 clinical trial evaluating Fluticasone furoate 50mcg and Placebo for Asthma. Completed, enrolled 248 participants across 24 sites in 4 countries.
Detailed Summary
A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesMexico, Peru, Russia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedSep 2011
Primary CompletionJun 2012
Study CompletionAug 2012
TodayJul 2026
First PostedSep 19, 2011
Enrollment StartSep 1, 2011
Primary CompletionJun 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.8 years ago
Interventions
Fluticasone furoate 50mcgdrug
Inhalation powder delivered by Novel Dry Powder Inhaler
Placebodrug
Inhalation powder delivered by Novel Dry Powder Inhaler